Ultragenyx Pharmaceutical (RARE) Other financing activities (2014 - 2025)
Ultragenyx Pharmaceutical (RARE) posted quarterly Other financing activities of $6.0 million for Q4 2025, up 50.0% year-over-year from $4.0 million in Q4 2024, and up 50.0% quarter-over-quarter from $4.0 million in Q4 2024.
Ultragenyx Pharmaceutical (RARE) Other financing activities (2014 - 2025) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Other financing activities for 12 consecutive years, with $6.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities rose 50.0% year-over-year to $6.0 million; the TTM figure through Dec 2025 stood at $17.0 million (up 54.55% YoY), while the FY2025 annual figure was $6.0 million, down 45.45% from the prior year.
- Other financing activities rose to $6.0 million in Q4 2025 per RARE's latest filing, from $4.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $40.5 million in Q4 2021 and bottomed at -$25.9 million in Q3 2021.
- Historically, Other financing activities has averaged $4.1 million across 5 years, with a median of $28000.0 in 2023.
- On a YoY basis, Other financing activities climbed as much as 44263.79% in 2021 and fell as far as 239.39% in 2021.
- Ultragenyx Pharmaceutical's Other financing activities stood at $40.5 million in 2021, then plunged by 98.92% to $436000.0 in 2022, then sank by 93.58% to $28000.0 in 2023, then soared by 14185.71% to $4.0 million in 2024, then jumped by 50.0% to $6.0 million in 2025.
- Business Quant data shows RARE's Other financing activities at $6.0 million in Q4 2025, $4.0 million in Q4 2024, and $7.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.00 Mn |
| Dec 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 7.00 Mn |
| Sep 30, 2024 | 7.00 Mn |
| Dec 31, 2023 | 28,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Jun 30, 2023 | -56,000.00 |
| Jun 30, 2023 | -56,000.00 |
| Mar 31, 2023 | 28,000.00 |
| Mar 31, 2023 | 28,000.00 |
| Dec 31, 2022 | 436,000.00 |
| Dec 31, 2022 | 436,000.00 |
| Sep 30, 2022 | -147,000.00 |
| Sep 30, 2022 | -147,000.00 |
| Jun 30, 2022 | -146,000.00 |
| Jun 30, 2022 | -146,000.00 |
| Mar 31, 2022 | -143,000.00 |
| Mar 31, 2022 | -143,000.00 |